ClinicalTrials.Veeva
Menu

Find clinical trials for COVID-19 in London, England

CTV is a public benefit provided by Veeva Systems to help you find the most relevant clinical trials for you and your loved ones

Related conditions:

Infections
Communicable Diseases
Coronavirus Infections
Pneumonia
Post-Acute COVID-19 Syndrome
Human Influenza
Syndrome

COVID-19 trials near London, England, GBR:

Inflammatory Signal Inhibitors for COVID-19 (MATIS)

The Multi-arm trial of Inflammatory Signal Inhibitors for COVID-19 (MATIS) study is a two-stage, open-label, randomised controlled -...

Enrolling
Covid19
Pneumonia
Drug: Ruxolitinib
Other: Standard of care

Phase 1, Phase 2

Imperial College London
Imperial College London

London, United Kingdom

PROphylaxis for paTiEnts at Risk of COVID-19 infecTion -V (PROTECT-V)

COVID-19 (SARS-CoV2 virus) was declared a global pandemic by the WHO on 11th March 2020. Currently there are no drugs proven to pre-...

Enrolling
Covid19
Drug: Placebo
Drug: Sotrovimab

Phase 2, Phase 3

NHS Foundation Trust
NHS Foundation Trust

London, United Kingdom and 44 other locations

A Study to Determine Safety and Immunogenicity of the Candidate COVID-19 Vaccine AZD1222 Delivered by Aerosol in Healthy Adult Volunteers (COVAXAER01)

This study will test the COVID-19 vaccine candidate AZD1222 to investigate its safety, tolerability and capability of boosting immu-...

Active, not recruiting
Covid19
SARS-CoV-2 Infection
Biological: 1x10^10 vp AZD1222
Biological: 5x10^9 vp AZD1222

Phase 1

Imperial College London
Imperial College London

London, United Kingdom

A Study of mRNA-1283.222 Injection Compared With mRNA-1273.222 Injection in Participants ≥12 Years of Age to Prevent COVID-19 (NextCOVE)

The purpose of this study is to evaluate the safety, reactogenicity, and relative vaccine efficacy (rVE) of the mRNA-1283.222 vaccine as well as its...

Active, not recruiting
COVID-19
Biological: mRNA-1273.222
Biological: mRNA-1283.222

Phase 3

Moderna
Moderna

London, United Kingdom and 217 other locations

Study Understanding Pre-Exposure pRophylaxis of NOVel Antibodies (SUPERNOVA) Sub-study: Study Understanding Pre-Exposure pRophylaxis of NOVel Antibodies (SUPERNOVA) Sub-study

known SARS-CoV-2 variants of concern for pre-exposure prophylaxis of COVID-19.The aim of the Phase I/III study (Parent Study) will -...

Active, not recruiting
COVID-19, SARS-CoV-2
Biological: AZD3152 (Sub-study)
Biological: Placebo (Parent study Sentinel Safety Cohort)

Phase 2, Phase 3

AstraZeneca
AstraZeneca

London, United Kingdom and 214 other locations

Study to Monitor the Occurrence of Viral Variants in Patients With Compromised Immune Systems Being Treated for COVID-19 (LUNAR)

prioritized to receive early treatment for COVID-19 as they are at high risk of disease progression, and because of their potentia...

Enrolling
COVID-19
Drug: Sotrovimab

Phase 4

GlaxoSmithKline (GSK)
GlaxoSmithKline (GSK)

London, United Kingdom and 6 other locations

Study to Evaluate Safety and Immunogenicity of COVID-19 Vaccine in Children 6 Months to < 12 Years (COVID-19)

This is a Phase 2/3 randomized, observer-blinded, placebo-controlled, age de-escalation trial to evaluate the safety and immunogenicity of 2 primary...

Active, not recruiting
COVID-19
Other: Placebo
Biological: SARS-CoV-2 rS/Matrix-M1 Adjuvant (Open Label Crossover Vaccination period)

Phase 2, Phase 3

Novavax
Novavax

London, United Kingdom and 95 other locations

Study of a Recombinant Coronavirus-Like Particle COVID-19 Vaccine in Adults

This Phase 2/3 study is a multi-portion design to confirm that the chosen formulation and dosing regimen of CoVLP has an acceptable immunogenicity an...

Active, not recruiting
SARS-CoV-2 Infection
Biological: Intramuscular vaccine
Drug: Intramuscular injection

Phase 2, Phase 3

Medicago

London, United Kingdom and 90 other locations

A Study in Healthy Volunteers to Evaluate the Safety, Tolerability, Pharmacokinetics, and Drug-Drug Interaction Potential of Single and Multiple Doses of ALG-097558

A multi-part study of ALG-097558 to evaluate safety, tolerability, pharmacokinetics and drug-drug interaction potential after single and multiple dos...

Active, not recruiting
COVID-19
Drug: ALG-097558 in solution formulation
Drug: Placebo

Phase 1

Aligos Therapeutics

London, United Kingdom

Dose, Safety and Pathogenicity of SARS-CoV-2 Omicron Virus (BA.5)

An Exploratory Study to Establish the Dose, Safety and Pathogenicity of a SARS-CoV-2 Omicron Challenge Strain (BA.5) in Healthy Participants 18 to 30...

Not yet enrolling
SARS-CoV-2 Infection
Biological: SARS-CoV-2 omicron virus dose arm 2
Biological: SARS-CoV-2 omicron virus dose arm 1

Early Phase 1

Hvivo

London, United Kingdom

Clinical trials

Find clinical trialsTrials by location

Research sites

Find research sitesLearn about CTV for professionals

Resources

Contact CTV support

Legal

Privacy NoticeTerms
© Copyright 2024 Veeva Systems